Seagen: CHMP Adopts Positive Opinion For TUKYSA - Quick Facts

Biotechnology company Seagen Inc. (SGEN) said Friday that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion for TUKYSA (tucatinib) for the treatment of patients with locally advanced or metastatic HER2-Positive breast cancer.

The CHMP positive opinion recommends the approval of TUKYSA in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.

The CHMP positive opinion will now be considered by the European Commission or EC, which has the authority to approve medicines in the European Union or EU.

TUKYSA is an oral, small molecule tyrosine kinase inhibitor (TKI) of HER2, a protein that contributes to cancer cell growth.

The positive CHMP opinion is based on results of the pivotal trial HER2CLIMB and were published in the New England Journal of Medicine in December 2019.

TUKYSA is approved in the U.S., Canada, Switzerland, Singapore and Australia.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwest Airlines' flights across the United States were delayed for hours on Monday evening due to technical issue in a weather information system by a third-party weather data provider. The airline later resumed flight operations after solving the issue, but there were delays. The United Kingdom's Competition and Markets Authority or CMA announced Tuesday that it has launched a market study into mobile ecosystems of technology giants Apple Inc. (AAPL) and Google, Inc. (GOOG) over concerns they have market power which is harming users and other businesses. The CMA is taking... Eli Lilly and Co. (LLY) announced Tuesday that it will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant), an orally disintegrating tablet patients take every other day. This study will help to advance the science of migraine treatment...
Follow RTT